La guida definitiva all'editing genico.
Menu
Home Scopri Notizie Chiedi all'Atlas
Esplora Tecnologie Malattie Trattamenti Sperimentazioni cliniche Aziende Scienziati Geni Ricerca Istituzioni
Oltre la medicina Agricoltura Etica Investimenti Mappa del mondo
Scopri e strumenti Inizia da qui Glossario A–Z Confronta le tecnologie Cronologia Elenchi e classifiche Agenti IA ★ Salvato API
Informazioni Chi siamo Metodologia Fonti dei dati Politica editoriale Contatti Note legali

🧭 Vista guidata
Sei nuovo alla genetica? Spieghiamo ogni termine mentre navighi, in parole semplici. Le stesse pagine, con il supporto già incluso.

⚡ Parere degli esperti
Conosci già la biologia. Solo i contenuti — chiari e compatti, senza spiegazioni aggiuntive. Questa è la visualizzazione predefinita.

Lingua dell'interfaccia
Modalità chiara

Confronto

CRISPR vs RNA Interference

A permanent change to the instructions, against a temporary attack on the copies.

La differenza in una frase

Both can reduce how much of a protein your body makes. CRISPR does it by changing the gene — once, permanently. RNA interference does it by destroying the working copies as they are made, which means repeating the treatment indefinitely but also being able to stop. For ATTR amyloidosis both approaches target the same gene, which makes the comparison unusually concrete.

AspettoCRISPR gene editingRNA interference
What it changes The gene itself The messages made from the gene
Permanence Permanent Temporary — repeat dosing required
Can it be stopped? No Yes — stop dosing and it wears off
Dosing Once Regularly, indefinitely
Safety data available A few years Years, from approved medicines in routine use
Clinical status One approved medicine Multiple approved medicines
Same-target example Nexiguran ziclumeran for ATTR Patisiran and vutrisiran for ATTR

Which is better?

Neither, in general. The editing approach offers one treatment instead of a lifetime of them. The RNAi approach offers years of accumulated safety data and the ability to stop if something goes wrong. For a young patient facing decades of injections, permanence looks attractive; for an older patient with other conditions, reversibility may matter more. It is the clearest illustration on this site that newer does not settle a clinical question.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

RNA Interference

Diseases

ATTR Amyloidosis